For years, Pharma have been itching to prove a benefit of extended chemoprophylaxis against DVT / PE in medically ill patients after hospital discharge. Three weeks or more of enoxaparin after surgical knee or hip replacement is standard care, since it reduces the high risk of serious venous thromboembolism with a relatively low risk of serious bleeding events. Although medically ill patients are also at risk for DVT/PE post-discharge, no benefit from extended prophylaxis has been shown. Bristol-Myers Squibb and Pfizer are the latest to seek a sales-boosting new indication for a novel anticoagulant, but their